Buy SPRY by May 12, 2029.

ARS Pharma stock went up over the last couple years thanks to its needle-free EpiPen getting FDA approval and data showing follow-up doses actually work better than EpiPens. But insiders were selling left and right, which can be rational diversification (you can’t jet ski on your stock options), but also a red flag about what management thinks the company is worth. The stock has fallen substantially this year, and lots of people are betting it will fall further. However, there …